Korean Journal of Radiology

  • 제2권2호
  • /
  • Pages.80-86
  • /
  • 2001
  • /
  • 1229-6929(pISSN)
  • /
  • 2005-8330(eISSN)
대한영상의학회 (The Korean Society of Radiology)
권호 표지

Human in-vivo 31P MR Spectroscopy of Benign and Malignant Breast Tumors

  • Jeong Mi Park (Department of Radiology, University of Ulsan-Asan Medical Center) ;
  • Jae Hyung Park (Department of Radiology, Seoul National University Hospital and The Institute of Radiation Medicine, Seoul National University Medical Research Center)
  • 투고 : 2000.08.25
  • 심사 : 2001.01.31
  • 발행 : 2001.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objective: To assess the potential clinical utility of in-vivo 31P magnetic resonance spectroscopy (MRS) in patients with various malignant and benign breast lesions. Materials and Methods: Seventeen patients with untreated primary malignant breast lesions (group I), eight patients with untreated benign breast lesions (group II) and seven normal breasts (group III) were included in this study. In-vivo 31P MRS was performed using a 1.5 Tesla MR scanner. Because of the characteristics of the coil, the volume of the tumor had to exceed 12 cc (3×2×2 cm), with a superoinferior diameter at least 3 cm. Mean and standard deviations of each metabolite were calculated and metabolite ratios, such as PME/PCr, PDE/PCr, T-ATP/PCr and PCr/T-ATP were calculated and statistically analyzed. Results: Significant differences in PME were noted between groups I and III (p=0.0213), and between groups II and III (p=0.0213). The metabolite ratios which showed significant differences were PME/PCr (between groups II and III) (p=0.0201), PDE/PCr (between groups I and III, and between groups II and III) (p=0.0172), T-ATP/PCr (between groups II and III) (p=0.0287), and PCr/T-ATP (between groups II and III) (p=0.0287). There were no significant parameters between groups I and II. Conclusion: In-vivo 31P MRS is not helpful for establishing a differential diagnosis between benign and malignant breast lesions, at least with relatively large lesions greater than 3 cm in one or more dimensions.

키워드

과제정보

The authors thank Seon-moon Hwang, RT, and his colleagues in our MR department for their generous support and assistance during this study. We also thank Bonnie Hami, Department of Radiology, University Hospitals Health System, Cleveland, Ohio, for her editorial assistance in preparing this manuscript.

참고문헌

  1. Aisen AM, Chenevert TL. MR spectroscopy : clinical perspective. Radiology 1989;173:593-599 https://doi.org/10.1148/radiology.173.3.2682768
  2. Bottomley PA. Human in-vivo NMR spectroscopy in diagnostic medicine : Clinical tool or research probe ? Radiology 1989;170:1-15 https://doi.org/10.1148/radiology.170.1.2642336
  3. Merchant TE. MR spectroscopy of the breast. Magn Reson Imaging Clin N Am 1994;2:691-703 https://doi.org/10.1016/S1064-9689(21)00134-3
  4. Yoon K-H, Lee M-G, Lee JH, Kim CG, Auh YH. In-vivo 31P magnetic resonance spectroscopy in liver cirrhosis : assessment of phosphorus metabolites according to hepatic dysfunction. J Korean Radiol Soc 1998;39:1171-1176 https://doi.org/10.3348/jkrs.1998.39.6.1171
  5. Oberhaensli RD, Hilton-Jones D, Bore PJ, et al. Biochemical investigation of human tumors in vivo with phosphorus-31 magnetic resonance spectroscopy. Lancet 1986;2(8497):8-11 https://doi.org/10.1016/S0140-6736(86)92558-4
  6. Weinreb JC, Newstead G. MR imaging of the breast. Radiology 1995;196:593-610 https://doi.org/10.1148/radiology.196.3.7644617
  7. Kaplan O, Cohen JS. Metabolism of breast cancer cells as revealed by non-invasive magnetic resonance spectroscopy studies. Breast Cancer Res Treat 1994;31:285-299 https://doi.org/10.1007/BF00666161
  8. Kvistad KA, Bakken IJ, Gribbestad IS, et al. Characterization of neoplastic and normal human breast tissues with in-vivo 1H MR spectroscopy. J Magn Reson Imaging 1999;10:159-164 https://doi.org/10.1002/(SICI)1522-2586(199908)10:2<159::AID-JMRI8>3.0.CO;2-0
  9. Mackinnon WB, Barry PA, Malycha PL, et al. Fine-needle biopsy specimens of benign breast lesions distinguished from invasive cancer ex vivo with proton MR spectroscopy. Radiology 1997;204:661-666 https://doi.org/10.1148/radiology.204.3.9280241
  10. Roebuck JR, Cecil KM, Schnall MD, Lenkinski RE. Human breast lesions: Characterization with proton MR spectroscopy. Radiology 1998;209:269-275 https://doi.org/10.1148/radiology.209.1.9769842
  11. Gribbestad IS, Singstad TE, Nilsen G, et al. In-vivo 1H MRS of normal breast and breast tumors using a dedicated double breast coil. J Magn Reson Imaging 1998;8:1191-1197 https://doi.org/10.1002/jmri.1880080602
  12. Gribbestad IS, Petersen SB, Fjosne HE, Kvinnsland S, Krane J. 1H NMR spectroscopic characterization of perchloric acid extracts from breast carcinomas and non-involved breast tissue. NMR Biomed 1994;7:181-194 https://doi.org/10.1002/nbm.1940070405
  13. Merchant TE, Thelissen GRP, Graaf PW, Otter WD, Glonek T. Clinical magnetic resonance spectroscopy of human breast disease. Invest Radiol 1991;26: 1053-1059 https://doi.org/10.1097/00004424-199112000-00003
  14. Kalra R, Wade KE, Hands L, et al. Phosphomonoester is associated with proliferation in human breast cancer : a 31P MRS study. Br J Cancer 1993;67:1145-1153 https://doi.org/10.1038/bjc.1993.211
  15. Sijen PE, Wijrdeman HK, Moerland MA, et al. Human breast cancer in vivo:H-1 and P-31 MR spectroscopy at 1.5T. Radiology 1988;169:615-620 https://doi.org/10.1148/radiology.169.3.2847230
  16. Twelves CJ, Porter DA, Lowry M, et al. Phosphorus-31 metabolism of post-menopausal breast cancer studied in vivo by magnetic resonance spectroscopy. Br J Cancer 1994;69:1151-1156 https://doi.org/10.1038/bjc.1994.226
  17. Leach MO, Verrill M, Glaholm J, et al. Measurements of human breast cancer using magnetic resonance spectroscopy : a review of clinical measurements and a report of localized 31P measurements of response to treatment. NMR Biomed 1998;11:314-340 https://doi.org/10.1002/(SICI)1099-1492(1998110)11:7<314::AID-NBM522>3.0.CO;2-Z
  18. Redmond OM, Stack JP, O'Conner NG, et al. In-vivo Phosphorus-31 magnetic resonance spectroscopy of normal and pathological breast tissues. Br J Radiol 1991;64:210-216 https://doi.org/10.1259/0007-1285-64-759-210
  19. Smith TAD, Bush C, Jameson C, et al. Phospholipid metabolites, prognosis and proliferation in human breast carcinoma. NMR Biomed 1993;6:318-323 https://doi.org/10.1002/nbm.1940060506
  20. Degani H, Furman E, Fields S. Magnetic resonance imaging and spectroscopy of MCF7 human breast cancer:pathophysiology and monitoring of treatment. Clinica Chemica Acta 1994;228:19-33 https://doi.org/10.1016/0009-8981(94)90054-X
  21. Singer S, Souza K, Thilly WG. Pyruvate utilization, phosphocholine and adenosine triphosphate(ATP) are markers of human breast tumor progression: a 31P- and 13C-nuclear magnetic resonance(NMR) spectroscopy study. Cancer Res 1995;55(22):5140-5145
  22. Merchant TE, Meneses P, Gierke LW, Otter WD, Glonek T. 31P Magnetic resonance phospholipid profiles of neoplastic human breast tissues. Br J Cancer 1991;63:693-698 https://doi.org/10.1038/bjc.1991.157
  23. Twelves CJ, Lowry M , Porter DA, et al. Phosphorus-31 metabolism of human breast an in-vivo magnetic resonance spectroscopic study at 1.5T. Br J Radiol 1994;67:36-45 https://doi.org/10.1259/0007-1285-67-793-36
  24. Degani H, Horowitz A, Itzchak Y. Breast tumors:evaluation with P-31 MR spectroscopy. Radiology 1986;161:53-55 https://doi.org/10.1148/radiology.161.1.3020609
  25. Merchant TE, Gierke LW, Meneses P, Glonek T. 31P magnetic resonance spectroscopic profiles of neoplastic human breast tissues. Cancer Res 1988;48:5112-5118